Loading stock data…
AstraZeneca PLC (AZN)
$160.04-2.66 (-1.63%)
Market ClosedLast close Sep 8
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AstraZeneca PLC in the Healthcare sector is trading at $160.04 with a market capitalization of $242.6B. Wall Street consensus targets $212.54 (11 analysts), implying a +32.8% move over the next 12 months. The stock is currently 25% below its 52-week high of $212.71, remaining 12.7% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +32.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.38B↑ | $15.29B↓ | $15.50B↑ | $15.19B↑ | $14.46B |
| Gross Profit | $12.86B↑ | $12.61B↑ | $12.38B | $12.39B↑ | $11.98B |
| Operating Income | $3.16B↓ | $4.25B↑ | $2.98B↓ | $3.58B↑ | $3.51B |
| Net Income | $2.51B↓ | $3.08B↑ | $2.33B↓ | $2.53B↑ | $2.45B |
Peer Comparison
JNJUNHPFE
Fundamentals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$242.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.42
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.35%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.77%
Volume
Today's trading volume
5.14M
Recent News
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.
AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test
The 563-patient study hit three efficacy endpoints, but investors still lack hazard ratios and regulatory timing.
Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon
All three major US stock indexes fell in late-morning trading Tuesday as oil prices climbed and inve
AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review
A committee said the volrustomig combination was unlikely to reach either of the primary endpoints for the trial, but the company said other Phase 3 volrustomig trials would continue as planned.
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.